Actively Recruiting
Phase II Study of Gemcitabine and Docetaxel Bladder Treatment Combined with Pembrolizumab for High-Risk Non-Muscle Invasive Bladder Cancer Patients Unresponsive or Previously Treated with BCG
Led by BLATAM · Updated on 2026-05-28
37
Participants Needed
1
Research Sites
23 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a treatment approach for patients with high-risk non-muscle invasive bladder cancer NMIBC who have not responded to or have been exposed to Bacillus Calmette-Guerin BCG therapy. This phase II, single-arm study investigates the combination of intravesical chemotherapy and systemic immunotherapy to assess safety and effectiveness over a one-year treatment period. Participants will receive intravesical chemotherapy, specifically docetaxel plus gemcitabine, administered every three weeks directly into the bladder. Alongside this, systemic pembrolizumab immunotherapy will be given intravenously every six weeks. The treatment duration is planned for one year, with the aim to evaluate both the efficacy and treatment-related adverse events. During the study, participants will be monitored for treatment response and side effects. The primary outcomes include measuring efficacy at three months and recording any treatment-related adverse events over one year using standard criteria. Assessments will involve clinical evaluations and ongoing safety monitoring throughout the treatment period, which lasts a total of 12 months.
CONDITIONS
Brief Title
Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy
Research Team
G
Gustavo M Villoldo, MD
M
Martin O Angel, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here